匹多莫德预防过敏性紫癜复发的42例临床观察

42 cases clinical observation on the recurrence of Henoch-Schonlein purpura by pidotimod

目的观察匹多莫德预防过敏性紫癜(HSP)复发的临床效果及相关因素分析。方法78例HSP患儿随机分为治疗组42例和对照组36例,30例健康儿童作为正常对照组。对照组常规治疗,治疗组加匹多莫德颗粒剂口服。观察住院期间、2个月内、6个月内的反复、复发率及测定治疗前、治疗2个月时血CD3+、CD4+、CD8+、白介素-2(IL-2)、γ-干扰素(IFN-γ)水平。结果HSP患儿治疗前血CD3+、CD4+、IL-2、IFN-γ水平均低于正常对照组(P均<0.01),CD8+细胞水平各组间无差异(P>0.05);治疗2个月后治疗组血CD3+、CD4+、IL-2、IFN-γ水平较对照组明显上升(P<0.01或P<0.05),与正常对照组无显著差异(P>0.05);住院期间治疗组的反复率与对照组比较无显著性差异(P>0.05);2个月及6个月内治疗组的复发率明显低于对照组(P<0.05)。结论匹多莫德能降低HSP患儿的复发率,可能与其对HSP患儿T细胞功能的调整密切相关。

Objective：To observe the clinical effect of Pidotimod for prevention of the recurrence of Henoch-Schonlein purpura（HSP） and analyze its related factors.Methods：62 children were divided randomly into the treatment group and the control group,the former was treated with common therapy and Pidotimod,and the latter was treated only with common therapy.Anther 30 healthy children were served as normal control group.We observed the rate of recurrence in hospitalization and in 2 months,6months,determined the level of CD3＋,CD4＋,CD8＋,IL-2,IFN-γ before and after 2 months＇ treatment.Results：Before treatment,the level of CD3＋,CD4＋,IL-2,IFN-γ in the treatment group were lower than those in normal control group（P〈0.01）;2 month after treatment,the level of CD3＋,CD4＋,CD8＋,IL-2,IFN-γ in the treatment group were higher than those in the control group（P〈0.01 or P〈0.05）,there was no difference between the treatment group and the normal control group（P〈0.05）;The rate of recurrence,there was no difference between the treatment group and the control group in hospitalization（P〉0.05）,but in 2 months and 6 months,the rate of recurrence in the treatment group was lower than that in the control group（P〈0.05）.Conclusion：Pidotimod can lower the recurrence of HSP,it is probably closely related to the adjustment of T cell subsets＇ function.